BGLAF (BioGaia AB) Short Interest


BGLAF BioGaia AB BGLAF
100 GF Score
Price $12.20
GF Value $13.05
! 5 Warning Signs
View Full Analysis

What is BioGaia AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

BGLAF vs ZTS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioGaia AB Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Short Interest distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Short Interest falls into.


BGLAF
100GF Score
BioGaia AB BGLAF
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioGaia AB (BGLAF) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued. The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.

Key valuation signals for BGLAF:

  • Short Interest:
  • GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
  • GF Score™: 100/100 with 5 warning signs

No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioGaia AB Business Description

Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score

Get the complete analysis for BGLAF

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.20
Price
$13.05
GF Value